Skip to content
HowShorted

AERIE PHARMACEUTICALS INC short interest in 2021

In 2021, AERIE PHARMACEUTICALS INC's disclosed short interest ran from 12.33% of shares outstanding on 15 Jan 2021 to 7.24% on 31 Dec 2021, a change of -5.09 percentage points. The year's high was 15.64% on 26 Feb 2021 and its low 7.24% on 31 Dec 2021, averaging 12.45% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.42 days on 31 Aug 2021. Full history: AERIE PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for AERIE PHARMACEUTICALS INC in 2021

2021 in figures

Start of year
12.33% (15 Jan 2021)
End of year
7.24% (31 Dec 2021)
Change
-5.09 pp
High
15.64% (26 Feb 2021)
Low
7.24% (31 Dec 2021)
Average
12.45%
Highest days to cover
20.42 (31 Aug 2021)
SEC filings marked
8

Every report in 2021

AERIE PHARMACEUTICALS INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202112.33%14.45
29 Jan 202113.20%4.78
12 Feb 202114.99%12.01
26 Feb 202115.64%15.17results (8-K), 10-K filed
15 Mar 202115.07%9.95
31 Mar 202114.94%15.34
15 Apr 202113.80%15.93
30 Apr 202114.28%18.81
14 May 202113.43%11.76results (8-K), 10-Q filed
28 May 202113.82%16.75
15 Jun 202113.94%13.78
30 Jun 202112.99%8.29
15 Jul 202111.46%13.94
30 Jul 202110.99%14.68
13 Aug 202111.05%13.48results (8-K), 10-Q filed
31 Aug 202110.62%20.42
15 Sep 202111.24%10.06
30 Sep 202115.29%4.68
15 Oct 202114.34%10.34
29 Oct 202112.24%6.94
15 Nov 20219.02%6.83results (8-K), 10-Q filed
30 Nov 20217.51%3.81
15 Dec 20219.46%2.27
31 Dec 20217.24%2.57

See also: AERIE PHARMACEUTICALS INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.